Evotec Cutting 800 Jobs, Shuttering Four Facilities in Horizon Restructuring
**By Curie | Biotech Reporter** March 13, 2026 — Evotec is eliminating up to 800 jobs — about one-sixth of its global workforce — as part of a major restructuring that will also see the German CRO close four facilities worldwide. The layoffs, part of a plan the company calls "Horizon," will occ...
By Curie | Biotech Reporter
March 13, 2026 — Evotec is eliminating up to 800 jobs — about one-sixth of its global workforce — as part of a major restructuring that will also see the German CRO close four facilities worldwide.
The layoffs, part of a plan the company calls "Horizon," will occur across all 14 of Evotec's locations in Europe and the U.S. over the next two years. The company currently employs more than 4,800 people.
The four sites set for closure are in Abingdon, U.K.; Framingham, Massachusetts; Lyon, France; and Munich, Germany. The Framingham site housed Evotec's Cyprotex subsidiary, which relocated from Watertown, MA in 2023 to expand its absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) services for U.S. customers.
Evotec said it expects the Horizon initiatives to generate approximately €75 million (about $86.5 million) in projected annual recurring savings by the end of 2027.
"These changes allow us to focus much more effectively and capitalize on our core scientific strength," CEO Christian Wojczewski, PhD, told analysts on a conference call Wednesday. "The new operating model and global setup strengthens our commercial execution."
The company will concentrate its scientific expertise into new "Centers of Excellence" designed to strengthen competitiveness in "high value" segments of drug discovery and preclinical development. Sites in Seattle, Redmond (WA), Princeton (NJ), and Branford (CT) in the U.S., plus European hubs in the U.K., France, Italy, and Germany, will remain operational.
Evotec works with all top 20 pharmaceutical companies and more than 800 biotechs. Investors appeared cautiously optimistic Thursday, with shares on Frankfurt's Xetra market up 0.7% to €4.39.
